GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (NAS:SNY) » Definitions » EV-to-EBITDA

SNY (Sanofi) EV-to-EBITDA : 12.94 (As of Oct. 31, 2024)


View and export this data going back to 2002. Start your Free Trial

What is Sanofi EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Sanofi's enterprise value is $151,359 Mil. Sanofi's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was $11,696 Mil. Therefore, Sanofi's EV-to-EBITDA for today is 12.94.

The historical rank and industry rank for Sanofi's EV-to-EBITDA or its related term are showing as below:

SNY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.96   Med: 10.61   Max: 14.55
Current: 12.84

During the past 13 years, the highest EV-to-EBITDA of Sanofi was 14.55. The lowest was 5.96. And the median was 10.61.

SNY's EV-to-EBITDA is ranked better than
55.13% of 711 companies
in the Drug Manufacturers industry
Industry Median: 14.78 vs SNY: 12.84

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-10-31), Sanofi's stock price is $52.88. Sanofi's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was $1.819. Therefore, Sanofi's PE Ratio (TTM) for today is 29.07.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Sanofi EV-to-EBITDA Historical Data

The historical data trend for Sanofi's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sanofi EV-to-EBITDA Chart

Sanofi Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.01 6.12 10.57 8.49 9.69

Sanofi Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 8.49 - 9.69 -

Competitive Comparison of Sanofi's EV-to-EBITDA

For the Drug Manufacturers - General subindustry, Sanofi's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sanofi's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sanofi's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Sanofi's EV-to-EBITDA falls into.



Sanofi EV-to-EBITDA Calculation

Sanofi's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=151358.894/11695.685
=12.94

Sanofi's current Enterprise Value is $151,359 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sanofi's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was $11,696 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sanofi  (NAS:SNY) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Sanofi's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=52.88/1.819
=29.07

Sanofi's share price for today is $52.88.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sanofi's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was $1.819.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Sanofi EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Sanofi's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Sanofi Business Description

Address
46, avenue de la Great Army, Paris, FRA, 75017
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. About 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Sanofi Headlines

From GuruFocus

Sanofi SA at Citi BioPharma Conference Transcript

By GuruFocus Research 02-09-2024

Sanofi SA Vaccines Investor Event Transcript

By GuruFocus Research 02-09-2024

Q2 2024 Sanofi SA Earnings Call Transcript

By GuruFocus Research 07-26-2024

Q2 2023 Sanofi SA Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q3 2022 Sanofi SA Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q3 2023 Sanofi SA Earnings Call Transcript

By GuruFocus Research 02-09-2024